5hmC as a Biomarker for Cancer in Combination with Ki67

DESCRIPTION
Diagnosis and staging of solid tumors is predominantly accomplished via biopsy, preparation of tissue sample slides, and examination under the microscope. Currently, the predominant diagnostic immunochemical test for cancer involves staining tissue samples with an antibody that marks proliferating cells (e.g. anti-Ki67 antibody). Rapidly dividing cells would indicate malignancy; however, not all malignant tumors contain large numbers of Ki67-positive cells and may be misdiagnosed.

Using sensitive and quantitative methods, City of Hope has identified a new immunohistological biomarker, 5-hydroxymethylcytosine (5hmC), that can distinguish normal tissue from tumor tissue. 5hmC is a DNA pyrimidine nitrogen base that is formed from cytosine by adding a methyl group and a hydroxyl group. An oxidation product of 5 methylcytosine (5mC) in mammalian DNA, 5hmC is suspected of being an intermediate step in epigenetic gene regulation via DNA methylation. Tumor cells are characterized by low levels of 5hmC and its tumor-associated loss presents a valuable means of improving diagnostic accuracy. By including 5hmC staining in the immunochemical preparation, alongside standard Ki67 staining, pathologists will be able to decrease false negatives and physicians will be able to begin proper cancer treatment for patients sooner.

KEY ASPECTS
- Immunohistology staining technique to improve accuracy in cancer diagnosis and staging

INTELLECTUAL PROPERTY

<table>
<thead>
<tr>
<th>Title</th>
<th>US Patent Application</th>
<th>Filed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Loss of 5-Hydroxymethylcytosine as a Biomarker for Cancer</td>
<td>61/589,231</td>
<td>1/20/2012</td>
</tr>
</tbody>
</table>

CONTACT
Matthew Grunseth, M.B.S.
Senior Manager, Office of Technology Licensing
Telephone: (626) 471-7221 | Email: mgrunseth@coh.org

This material is a summary of public domain and non-confidential City of Hope information. Additional material may be disclosed under a confidentiality agreement.

MK 12-089